Avalyn Adds Former FDA Leader to Board as Clinical Trials Advance
Event summary
- Avalyn Pharma appointed Robert J. Meyer, MD, a former FDA leader and pulmonologist, to its Board of Directors on September 16, 2026.
- Dr. Meyer brings over 25 years of experience in regulatory, academic, and industry roles, including senior positions at the FDA and Merck.
- Avalyn is advancing three inhaled therapy programs: AP01 (pirfenidone), AP02 (nintedanib), and AP03 (combination therapy).
- AP01 is in a global Phase 2b trial (MIST) for progressive pulmonary fibrosis, while AP02 is in a Phase 2 trial (AURA) for idiopathic pulmonary fibrosis.
The big picture
Avalyn's appointment of Dr. Meyer underscores its focus on regulatory and clinical expertise as it navigates the complex landscape of rare respiratory diseases. The move comes as the company advances multiple inhaled therapy candidates, aiming to address tolerability challenges of existing treatments. The biopharmaceutical sector is increasingly focused on targeted therapies for underserved patient populations, and Avalyn's approach could set a new standard if successful.
What we're watching
- Regulatory Strategy
- How Dr. Meyer's FDA experience will shape Avalyn's regulatory approach for its inhaled therapies.
- Clinical Execution
- The pace at which Avalyn can advance AP01, AP02, and AP03 through late-stage trials.
- Market Positioning
- Whether Avalyn can differentiate its inhaled formulations in the competitive pulmonary fibrosis space.